(Health Times reporter Gao Ruirui) On March 16, the Shandong Provincial Public Resource Trading Center issued a notice on publicizing the price adjustment of the fifth batch of medicines that were not selected for centralized procurement by the state.
The content of the notice shows that in accordance with the requirements of the “Price Adjustment Plan for Unselected Drugs in Centralized Procurement of National Organizations” (Lu Gong Zi Jiao Zi [2019] No. 48), the fifth batch of centralized procurement organized by some countries has not been selected. The adjustment of drug prices will be announced from March 17 to March 21, 2022.
The reporter combed the public information and found that there are a total of 195 drugs adjusted this time, 34 are suspended from trading, 161 A normal hookup. In addition, 83 drugs have passed the consistency evaluation of quality and efficacy, and 6 are imported original drugs. The reasons for the suspension of trading include over-evaluation of more than three companies, voluntary withdrawal from the Internet, and the price of over-evaluated drugs being higher than the price of original drugs.
Among them, 2 drugs were suspended due to duplicate products, namely alfacalcidol soft capsules of Chia Tai Pharmaceutical (Qingdao) Co., Ltd., and fat of Fresenius Kabi Huarui Pharmaceutical Co., Ltd. Lactic acid (17) glucose (11%) injection; 11 drugs were suspended due to over-review of over three companies, including acyclovir tablets of Chifeng Mengxin Pharmaceutical Co., Ltd. and Chlorochlorine of Jinan Yongning Pharmaceutical Co. Potassium Sustained-Release Tablets, Medium/Long Chain Fat Emulsion Injection from Xi’an Libang Pharmaceutical, Ceftriaxone Sodium for Injection from Harbin Pharmaceutical Group Pharmaceutical Factory, Levofloxacin Hydrochloride Sodium Chloride Injection from Shandong Qidu Pharmaceutical, Yangzijiang Pharmaceutical Industry Group Co., Ltd. Levofloxacin Hydrochloride Sodium Chloride Injection, etc.
In addition, there were 7 drugs whose prices were higher than the original drug prices and were suspended from trading, including Hangzhou Minsheng Pharmaceutical Co. Trisone sodium, ceftriaxone sodium for injection from Shanghai SPH Xinya Pharmaceutical Co., Ltd., ceftriaxone sodium for injection from Chengdu Beite Pharmaceutical Co., Ltd., ceftriaxone sodium for injection from Kunming Jida Pharmaceutical Co., Ltd., Shanghai SPH Xinya Pharmaceutical Co., Ltd. Industrial Co., Ltd. Solvent Crystallized Powder Injection, Shanghai Xinfeng Pharmaceutical Co., Ltd. Ceftriaxone Sodium for Injection.
Shandong Provincial Public Resource Trading Center stated that “multi-package drugs that do not meet the price difference”, “over-evaluated drugs are more expensive than original research drugs”, “unevaluated drugs are more expensive than selected drugs”, “unreviewed drugs are more expensive than selected drugs”. The price of over-evaluated basic drugs is higher than the price of selected drugs”, etc., the company can adjust it according to the price adjustment requirements during the publicity period (through the “Shandong Provincial Pharmaceutical Equipment Centralized Purchasing Platform”-“Drug Basic Library”-“Supply Information”- “Drug information” – “price reduction” self-adjustment). After adjustment, if it still does not meet the requirements, the transaction will be suspended.